EXPRESSION OF ERGOTOPE-ASSOCIATED MARKERS BY ACTIVATED T-LYMPHOCYTES

Abstract. Anti-ergotypic response is considered to contribute significantly to the regulation of immune response. Ergotope-associated antigenic determinants include molecules upregulated on the surface of activated T cells (CD25, hsp60 and others). Anti-ergotypic cells are directed against these sur...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	O. Yu. Korol’kova, V. V. Senyukov, V. S. Kozhevnikov
Formato:	article
Lenguaje:	RU
Publicado:	SPb RAACI 2014
Materias:	ergotope anti-ergotypic response т-lymphocytes Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/ff79062105fe43ca95b8a4edf30cdde2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ff79062105fe43ca95b8a4edf30cdde2
record_format	dspace
spelling	oai:doaj.org-article:ff79062105fe43ca95b8a4edf30cdde22021-11-18T08:03:40ZEXPRESSION OF ERGOTOPE-ASSOCIATED MARKERS BY ACTIVATED T-LYMPHOCYTES1563-06252313-741X10.15789/1563-0625-2009-2-3-256-260https://doaj.org/article/ff79062105fe43ca95b8a4edf30cdde22014-07-01T00:00:00Zhttps://www.mimmun.ru/mimmun/article/view/313https://doaj.org/toc/1563-0625https://doaj.org/toc/2313-741XAbstract. Anti-ergotypic response is considered to contribute significantly to the regulation of immune response. Ergotope-associated antigenic determinants include molecules upregulated on the surface of activated T cells (CD25, hsp60 and others). Anti-ergotypic cells are directed against these surface determinants usually complexed to MHC-I and/or MHC-II. Here we demonstrate regulated expression of HLA-Dr, СD25, hsp60 and hTERT mRNA during in vitro activation of peripheral T-lymphocytes with anti-CD3 antibodies and IL - 2, with reactivation on day 7. The percentage of CD25-expressing T cells showed sharp increase as early, as by the day 3 of activation, and it varied only slightly at later terms. The hsp60 levels rose as well, reached a peak at day 3, and gradually decreased thereafter. HLA-Dr expression was induced upon the activation, with a peak at the days 8 or 10. hTERT mRNA amounts also increased, as compared with baseline values, showing two peaks at the days 3 and 8. Anti-ergotopic response may control autoimmunity by targeting the activated T cells, regardless of their specificity. Therefore, immunotherapy of different autoimmune disorders aiming to activate anti-ergotopic responses, may be of a sufficient clinical interest.O. Yu. Korol’kovaV. V. SenyukovV. S. KozhevnikovSPb RAACIarticleergotopeanti-ergotypic responseт-lymphocytesImmunologic diseases. AllergyRC581-607RUMedicinskaâ Immunologiâ, Vol 11, Iss 2-3, Pp 256-260 (2014)
institution	DOAJ
collection	DOAJ
language	RU
topic	ergotope anti-ergotypic response т-lymphocytes Immunologic diseases. Allergy RC581-607
spellingShingle	ergotope anti-ergotypic response т-lymphocytes Immunologic diseases. Allergy RC581-607 O. Yu. Korol’kova V. V. Senyukov V. S. Kozhevnikov EXPRESSION OF ERGOTOPE-ASSOCIATED MARKERS BY ACTIVATED T-LYMPHOCYTES
description	Abstract. Anti-ergotypic response is considered to contribute significantly to the regulation of immune response. Ergotope-associated antigenic determinants include molecules upregulated on the surface of activated T cells (CD25, hsp60 and others). Anti-ergotypic cells are directed against these surface determinants usually complexed to MHC-I and/or MHC-II. Here we demonstrate regulated expression of HLA-Dr, СD25, hsp60 and hTERT mRNA during in vitro activation of peripheral T-lymphocytes with anti-CD3 antibodies and IL - 2, with reactivation on day 7. The percentage of CD25-expressing T cells showed sharp increase as early, as by the day 3 of activation, and it varied only slightly at later terms. The hsp60 levels rose as well, reached a peak at day 3, and gradually decreased thereafter. HLA-Dr expression was induced upon the activation, with a peak at the days 8 or 10. hTERT mRNA amounts also increased, as compared with baseline values, showing two peaks at the days 3 and 8. Anti-ergotopic response may control autoimmunity by targeting the activated T cells, regardless of their specificity. Therefore, immunotherapy of different autoimmune disorders aiming to activate anti-ergotopic responses, may be of a sufficient clinical interest.
format	article
author	O. Yu. Korol’kova V. V. Senyukov V. S. Kozhevnikov
author_facet	O. Yu. Korol’kova V. V. Senyukov V. S. Kozhevnikov
author_sort	O. Yu. Korol’kova
title	EXPRESSION OF ERGOTOPE-ASSOCIATED MARKERS BY ACTIVATED T-LYMPHOCYTES
title_short	EXPRESSION OF ERGOTOPE-ASSOCIATED MARKERS BY ACTIVATED T-LYMPHOCYTES
title_full	EXPRESSION OF ERGOTOPE-ASSOCIATED MARKERS BY ACTIVATED T-LYMPHOCYTES
title_fullStr	EXPRESSION OF ERGOTOPE-ASSOCIATED MARKERS BY ACTIVATED T-LYMPHOCYTES
title_full_unstemmed	EXPRESSION OF ERGOTOPE-ASSOCIATED MARKERS BY ACTIVATED T-LYMPHOCYTES
title_sort	expression of ergotope-associated markers by activated t-lymphocytes
publisher	SPb RAACI
publishDate	2014
url	https://doaj.org/article/ff79062105fe43ca95b8a4edf30cdde2
work_keys_str_mv	AT oyukorolkova expressionofergotopeassociatedmarkersbyactivatedtlymphocytes AT vvsenyukov expressionofergotopeassociatedmarkersbyactivatedtlymphocytes AT vskozhevnikov expressionofergotopeassociatedmarkersbyactivatedtlymphocytes
_version_	1718422520309219328

EXPRESSION OF ERGOTOPE-ASSOCIATED MARKERS BY ACTIVATED T-LYMPHOCYTES

Ejemplares similares